Back to ACA overview

Arcosa: The CRH Take-Out Bid and the Last Operating Print

Published August 16, 202620 min read·TickerFile Research · Arcosa, Inc. (ACA)

Arcosa, Inc. is no longer a standalone investment thesis; it is a closing arbitrage. On June 21, 2026, Ireland-headquartered CRH plc agreed to acquire the Dallas-based infrastructure company for $150.00 per share in cash, an enterprise value of approximately $8.5 billion including assumed debt, and the Board has scheduled a stockholder vote for September 4, 2026. The deal is not subject to a financing condition and is expected to close in the first quarter of 2027, subject to Hart-Scott-Rodino antitrust review plus clearances in Australia, Mexico, and potentially Canada. The single equity question for the next seven months is no longer whether the operating business compounds from here, but whether the merger closes, breaks, or is renegotiated, and what the holders of the 49.1 million shares of common stock are paid in each scenario.

Against that backdrop, Q2 2026 (the three months ended June 30, 2026) was the second-to-last independent quarterly print. Continuing-operations revenue rose 1.7% year over year to $658.7 million, with the Construction Products segment at $357.0 million (+0.7%) and Engineered Structures at $301.7 million (+3.0%). Operating profit was $84.3 million (12.8% margin), and diluted earnings from continuing operations held flat at $1.03 per share. Stripping out the April 2026 sale of the barge business (the Transportation Products segment, now in discontinued operations) and a $19.7 million gain on the disposition recorded in other operating income, the underlying margin story is a mid-single-digit top-line lift against elevated selling, general, and administrative expense that swallowed the gross-profit gain.

The stock closed August 11, 2026 at $144.91, a roughly 3.5% discount to the $150.00 cash deal price, which is the cleanest read on the market's assessment of closing risk and time-value-of-money. The next data points that test the thesis are the September 4 stockholder vote and the HSR/antitrust review, with regulatory clearance in Australia and Mexico layered on top.